Last week, a new retrospective study from Tongji Hospital in Wuhan was published in Science China Life Sciences (a Springer Link journal). The study found 47% fatalities in critically ill #COVID19 patients that were given regular treatment, and only 19% fatalities in patients treated with low doses of hydroxychloroquine (HCQ).
These results sound amazing.
But I took a closer look. And I have lots of questions.
Continue reading “Low dose of hydroxychloroquine – but lots of questions”In the past few years I have found some examples of papers showing photos of mice or rats with very large tumors. Some of these tumors appear to go far beyond what animal ethics guidelines consider to be acceptable.
This post contains images that might be disturbing to some viewers. So, please proceed with caution.
Continue reading “Animal ethics misconduct: mice with very large tumors”Recently a paper published in Nucleic Acid Therapeutics, a Mary Liebert publication not to be confused with the more glamorous Nucleic Acid Research journal, was brought to my attention. It described the potential use of small RNAs as a therapeutic against SARS-CoV-2.
Alas, it is most memorable because of the alarmingly short time-to-acceptance, lack of references, and the omission of several conflicts of interest.
Continue reading “COVID-19, small RNAs, and conflicts of interest”
Science Integrity Digest 